Aptose (APTO) to delist from Nasdaq April 2 for equity non-compliance

Aptose Biosciences Inc.

Nasdaq determined to delist Aptose common shares effective April 2, 2025 for failure to meet equity requirement (Listing Rule 5550(b)(1)).
Company confirmed on March 31, 2025 it could not regain compliance by the Panel's final extended deadline.
Trading suspended at open on April 2; shares continue trading on TSX under symbol APS.
Board reviewing options, including possible appeal; company seeks to relist on a U.S. exchange at appropriate time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.